Blueprint Medicines Corp. has synthesized new diazepanone-fused pyrimidines acting as epidermal growth factor receptor (EGFR) (mutant) and/or HER2 (mutant) inhibitors reported to be useful for the treatment of cancer, atherosclerosis, eczema and psoriasis.